Joel Beatty

Stock Analyst at Baird

(4.53)
# 184
Out of 5,180 analysts
213
Total ratings
48.52%
Success rate
33.36%
Average return

Stocks Rated by Joel Beatty

Denali Therapeutics
Mar 26, 2026
Maintains: Outperform
Price Target: $29$32
Current: $19.68
Upside: +62.60%
Immutep
Mar 13, 2026
Downgrades: Neutral
Price Target: $7$1
Current: $0.37
Upside: +170.27%
Dianthus Therapeutics
Mar 10, 2026
Maintains: Outperform
Price Target: $67$132
Current: $84.56
Upside: +56.10%
Contineum Therapeutics
Mar 6, 2026
Maintains: Outperform
Price Target: $14$20
Current: $13.45
Upside: +48.70%
Praxis Precision Medicines
Feb 20, 2026
Maintains: Outperform
Price Target: $275$433
Current: $319.28
Upside: +35.62%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72$47
Current: $21.42
Upside: +119.42%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160$209
Current: $188.27
Upside: +11.01%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145$125
Current: $62.30
Upside: +100.64%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10$19
Current: $14.35
Upside: +32.40%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10$7
Current: $4.68
Upside: +49.57%
Maintains: Outperform
Price Target: $4$6
Current: $2.61
Upside: +129.89%
Maintains: Neutral
Price Target: $7$9
Current: $35.24
Upside: -74.46%
Maintains: Outperform
Price Target: $28$31
Current: $22.32
Upside: +38.89%
Downgrades: Neutral
Price Target: $38$24
Current: $21.66
Upside: +10.80%
Upgrades: Outperform
Price Target: $680
Current: $743.12
Upside: -8.49%
Maintains: Outperform
Price Target: $70$66
Current: $68.75
Upside: -4.00%
Maintains: Outperform
Price Target: $160$162
Current: $171.78
Upside: -5.69%
Maintains: Outperform
Price Target: $38$41
Current: $35.05
Upside: +16.98%
Maintains: Outperform
Price Target: $28$32
Current: $24.82
Upside: +28.93%
Initiates: Outperform
Price Target: $75
Current: $71.72
Upside: +4.57%
Maintains: Neutral
Price Target: $72$65
Current: $57.24
Upside: +13.56%
Maintains: Outperform
Price Target: $540$240
Current: $0.24
Upside: +98,828.28%
Downgrades: Neutral
Price Target: $4.5
Current: $1.66
Upside: +171.08%
Maintains: Outperform
Price Target: $24$25
Current: $15.48
Upside: +61.50%
Maintains: Outperform
Price Target: $32$28
Current: $23.88
Upside: +17.25%
Initiates: Outperform
Price Target: $16
Current: $1.23
Upside: +1,200.81%
Maintains: Outperform
Price Target: $4$1.25
Current: $1.71
Upside: -26.90%
Initiates: Outperform
Price Target: $44
Current: $1.32
Upside: +3,233.33%
Maintains: Outperform
Price Target: $60$58
Current: $62.92
Upside: -7.82%
Maintains: Outperform
Price Target: $18$24
Current: $32.48
Upside: -26.11%
Downgrades: Underperform
Price Target: $18
Current: $7.85
Upside: +129.30%
Maintains: Outperform
Price Target: $9$6
Current: $1.61
Upside: +272.67%
Upgrades: Neutral
Price Target: $36$28
Current: $9.02
Upside: +210.42%
Downgrades: Neutral
Price Target: $170$175
Current: $328.73
Upside: -46.76%
Downgrades: Neutral
Price Target: $14
Current: $7.07
Upside: +98.02%
Downgrades: Neutral
Price Target: $108
Current: $22.13
Upside: +388.03%
Maintains: Buy
Price Target: $80$78
Current: $75.13
Upside: +3.82%
Maintains: Buy
Price Target: $140$100
Current: $20.50
Upside: +387.80%
Maintains: Buy
Price Target: $480$120
Current: $14.64
Upside: +719.67%
Maintains: Buy
Price Target: $480$450
Current: $4.35
Upside: +10,244.83%
Upgrades: Buy
Price Target: n/a
Current: $2.61
Upside: -
Maintains: Buy
Price Target: $19$15
Current: $8.02
Upside: +87.03%
Upgrades: Neutral
Price Target: $14$11
Current: $11.13
Upside: -5.66%
Maintains: Neutral
Price Target: $2,400$1,200
Current: $0.36
Upside: +334,534.69%
Maintains: Buy
Price Target: $15$19
Current: $8.34
Upside: +127.82%